Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Cynthia, and I will be your conference operator today.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 1,184,456 | $229,594,951 | +21% | 2.64% |
| 2. | Renaissance Technologies Jim Simons | 952,706 | $184,672,531 | +55% | 0.27% |
| 3. | GLG Partners Noam Gottesman | 856,835 | $166,088,896 | +1388% | 0.43% |
| 4. | OrbiMed Advisors Samuel Isaly | 813,000 | $157,591,920 | -10% | 2.86% |
| 5. | D E Shaw D. E. Shaw | 434,939 | $84,308,576 | +103% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $222.54 | 455 | Director | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | Director | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | Officer, Director | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | Director | 643,000 | 2019-05-02 | Filing | |
| $229.46 | 30,000 | Director | 605,000 | 2019-05-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $204.22 | 431 | Officer | 5,316 | 2024-09-03 | Filing | |
| $213.09 | 93 | Officer | 4,886 | 2024-04-02 | Filing | |
| $221.23 | 262 | Officer | 4,886 | 2024-02-22 | Filing | |
| $221.49 | 108 | Officer | 5,148 | 2024-02-16 | Filing | |
| $239.45 | 419 | Officer | 4,516 | 2024-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,264,481 | $4,208,759,748 | 3.33% | |
| 2. | 14,407,330 | $3,728,184,783 | 0.08% | |
| 3. | 14,246,658 | $3,686,607,689 | 0.09% | |
| 4. | 6,945,665 | $1,797,329,732 | 0.08% | |
| 5. | 5,324,396 | $1,377,793,953 | 0.25% |
News See All
10 Worst Performing NASDAQ Stocks in 2024
Markets have been soaring for the better part of the year, with pullbacks acting as entry levels from where investors have joined and pushed the market higher.
10 Oversold Large Cap Stocks To Buy Now
The Fed recently reduced the funds rate by 50 basis points, a decision seen as daring by some analysts, though it has been largely embraced by the market and many experts.
10 Best QQQ Stocks to Buy According to Analysts
Several recent discussions have focused solely on the implications of the Fed's recent rate cut for the market.
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks.
8 Best Bargain Stocks To Buy in October
September has historically been sluggish for stocks. However, with an easing cycle and an upcoming election in store, the results this year may be untypical.
Biogen Inc. (NASDAQ:BIIB) Q2 2024 Earnings Call Transcript
Operator: Good morning. My name is Anna and I will be your conference operator today.
Is Biogen (BIIB) an Underappreciated Stock?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Morgan Stanley's Top 15 Stock Picks for 2024
In this article, we'll look into Morgan Stanley's top 15 stock picks for 2024.
Billionaire Hedge Funds
